Director Allen Monty K disclosed a sale of 1,000 shares of IRADIMED CORP common stock on February 13, 2026, according to a Form 4 filing submitted to the Securities and Exchange Commission.
The shares were disposed of at a weighted average price of $100.2563, with trade prices ranging from $100.00 to $100.26, producing an aggregate transaction value of $100,256. After the sale, Allen directly holds 21,000 shares of the company.
At the time of the filing, IRADIMED was trading close to its 52-week high of $107.90 and has returned 83.6% over the trailing 12 months. The company carries a market capitalization of $1.27 billion.
Valuation and financial-health data cited from InvestingPro note that IRADIMED is trading at a price-to-earnings ratio of 57.5, a level the service characterizes as suggesting the stock may be overvalued versus current earnings. The same InvestingPro assessment assigns IRADIMED an overall financial health score of "GREAT" and expects the company to remain profitable through the year.
Investors seeking deeper analysis are pointed to the platform's Pro Research coverage, which includes IRADIMED among more than 1,400 U.S. equities evaluated with detailed reports.
Separately, Iradimed Corporation posted fourth-quarter 2025 results that beat analyst expectations, with both earnings per share and revenue coming in ahead of forecasts. While the company’s stock showed movement in pre-market trading following the release, the focus of the filings and reporting here is on the underlying earnings beat rather than intraday price action.
Market participants and analysts are likely to revisit ratings and financial projections in light of the stronger-than-expected quarterly performance. The earnings announcement arrives amid a sequence of recent company updates, and investors will be monitoring any additional disclosures from Iradimed Corporation.
This filing and the earnings disclosure together provide investors with contemporaneous information on insider activity, company performance, and valuation metrics, each of which may inform assessment of the equity going forward.